Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held Agensys brings a proprietary portfolio of cancer targets, a preclinical pipeline of mAbs and small proteins, and antibody manufacturing capabilities.
You may also be interested in...
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards
Astellas Wins OSI But Victory Comes At A Price
After months of drama, Astellas ups its bid to $4 billion cash to seal its hostile-turned-friendly bid for Tarceva maker OSI.